Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (7309)	1/22/2004 6:30:27 PM
From: Icebrg	Read Replies (1) \| Respond to of 10280

>>Sepr has a higher r&d budget than FRX, a company with a market cap 8X sepr. I don't think this is a good thing>> It is too early to tell if it is good or not. If they get their next two drugs approved they will be looking very good. Three (sort of) approved drugs, their own 900 headed sales force and a pipeline that still is filled with prospects. The question is - as always - not primarily how much they spend, but what we are getting for the money. With a mix of luck and skill Southwell has managed to get the company out of the financial hole they had been digging for themselves in anticipation of the SOLTARA approval. Erik